Genetic modification of bacteria to rapidly generate economcal vaccines for bacterial infections

Allan Saul of the Novartis Vaccines Institute for Global Health in Italy will genetically modify gram-negative bacteria to generate large quantities of their outer membranes, which can be loaded with antigens that stimulate immune responses. This technology could prove to be a reliable and economic platform for the generation of new vaccines.

Project Stage

Development & Testing

Implementation time

1 - 6 months

Last update: October 05, 2023

Overview Contributors

Challenge

Bacterial infections pose a significant health threat globally, especially in low- and middle-income countries. Traditional vaccine production methods are often expensive and time-consuming, which limits their accessibility and effectiveness.

Description

The project involves genetically modifying gram-negative bacteria to produce large quantities of their outer membranes. These membranes can then be loaded with various antigens that stimulate immune responses, making it a potentially efficient and cost-effective platform for creating new vaccines.

SDGs

Outcomes

The project aims to develop a reliable and economic platform for generating new vaccines, thereby improving accessibility to vaccination and reducing the impact of bacterial infections.